Key result
YM337 prevents occlusive thrombus formation in a monkey model, unlike aspirin and sodium ozagrel.
Why the study?
Does YM337 inhibit platelet aggregation and prevent thrombus formation in monkey models compared to aspirin or sodium ozagrel?
Does YM337 inhibit platelet aggregation and prevent thrombus formation in monkey models compared to aspirin or sodium ozagrel?
YM337, a short-acting anti-GPIIb/IIIa monoclonal antibody fragment, effectively inhibits platelet aggregation and prevents occlusive thrombus formation in monkey models.
Answers are grounded in this paper and cite their sources.
YM337 merits human thrombosis trials; leaves open superiority to aspirin or ozagrel in patients.
The antiplatelet and antithrombotic effects of the Fab fragment of the humanized antiplatelet glycoprotein (GP) IIb/IIIa monoclonal antibody C4G1 (YM337) were investigated in monkeys. First, the relationship between the inhibition of platelet aggregation and the prolongation of bleeding time was studied in rhesus monkeys. YM337 dose-dependently inhibited ex vivo platelet aggregation, with complete inhibition at doses higher than 0.25 mg/kg intravenous injection or 1.5 micrograms/kg/min infusion. At 0.25 mg/kg bolus injection followed by 1.5 micrograms/kg/min infusion, YM337 immediately and continuously inhibited platelet aggregation during the 6-h infusion period with platelet aggregation rapidly returning to over 50% of baseline within 1 h after the cessation of infusion. Template-bleeding time was significantly prolonged during the period of complete inhibition of platelet aggregation. Second, the antithrombotic effects of YM337 were investigated in a photochemically-induced thrombosis model in squirrel monkeys. YM337 at a dose of 1 mg/kg intravenous injection followed by 6 micrograms/kg/min infusion for 60 min prevented occlusive thrombus formation in all 4 monkeys. In contrast, time to occlusive thrombus formation did not change on intravenous bolus injection of aspirin 17 mg/kg (11.3 +/- 5.2 min) or sodium ozagrel (9.4 +/- 3.0 min) compared with saline (13.3 +/- 4.0 min). YM337 but not aspirin or sodium ozagrel significantly inhibited ex vivo ADP-induced platelet aggregation, while all drugs completely inhibited arachidonic acid-induced platelet aggregation. However, while aspirin and sodium ozagrel inhibited the thromboxane B2 generation accompanying arachidonic acid-induced platelet aggregation, YM337 had no effect on this variable. Platelet counts and bleeding time showed no significant change in any group in this squirrel monkey model. These results indicate that YM337, with a short half-life, may be a useful therapeutic agent in patients with thrombotic disorders.
No takes yet. Share an insight, caveat, or question.
Kaku et al. (1996) studied Thrombosis. YM337 vs. Aspirin, sodium ozagrel, or saline was evaluated on Time to occlusive thrombus formation. YM337 prevented occlusive thrombus formation in a monkey thrombosis model, whereas aspirin and sodium ozagrel did not significantly change the time to occlusion compared with saline.
Synapse has enriched 10 related papers. Consider them for comparative context: